VR Logo

Cara Therapeutics Inc. (CARA) download report


Healthcare | Biotechnology & Pharma Research

Cara Therapeutics Inc. (CARA) Premium Coverage

53 Stocks to buy right now

Join Value Research Stock Advisor now and be among the first to discover Stock Ideas

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

ajax-loader
Please wait...

About The Company

Business: Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States.

IPO Date: 31-Jan-2014

Pres, CEO & Director: Mr. Christopher A. Posner

Co-Founder & Sr. Advisor: Dr. Derek T. Chalmers D.Sc., Ph.D.

Listing: NASDAQ: CARA

Country: United States

Headquarters: Stamford, CT

Website: https://www.caratherapeutics.com

Key Facts

Market cap: $514.48 Mln

Revenue (TTM): $25.88 Mln

Earnings (TTM): $-92.89 Mln

Cash: $141.11 Mln

Total Debt: $3.25 Mln

Insider's Holding: 16.24%

Liquidity: Low

52 Week range: $7.41 - 18.93

Shares outstanding: 53,591,200

10 Years Aggregate:

  • CFO: $-341.63 Mln
  • EBITDA: $-427.01 Mln
  • Net Profit: $-428.49 Mln

Stock Performance

Time Period Cara Therapeutics (CARA) S&P BSE Sensex S&P Small-Cap 600
YTD-29.23-9.18-18.78
1 month4.61-4.78-8.00
3 months-29.05-9.66-13.65
1 Year-39.590.81-17.19
3 Years-26.2610.336.10
5 Years-10.9511.345.87
10 Years--11.749.84
As on 01-Jul-2022
Year Cara Therapeutics (CARA) S&P Small-Cap 600 S&P BSE Sensex
2021-19.5025.2721.99
2020-6.089.5715.75
201923.9220.8614.38
20186.17-9.705.87
201731.7511.7327.91
2016-44.9024.741.95
201569.11-3.36-5.03